Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

AZD6244 in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

Study:

A Phase II Trial of AZD6244 (NSC #748727, IND #77782) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Rationale:

AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Purpose:

This phase II trial is studying the side effects and how well AZD6244 works in treating patients with recurrent low-grade ovarian cancer.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Ovarian Cancer
Peritoneal Cavity Cancer
Drug: selumetinib
Genetic: mutation analysis
Genetic: protein expression analysis
Other: immunohistochemistry staining method
Other: pharmacological study
Phase 2

Verified by Gynecologic Oncology Group October, 2009

Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00551070

Study Type: Interventional

Study Design: Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio 44111
United States

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

John H. Farley, MD., Study Chair
David M. Gershenson, MD.,

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site